|
|
Post by golfeveryday on Jun 27, 2018 18:15:57 GMT -5
a CGM company that wants to lead could partner with MNKD/Afrezza or a BP could simply buy a CGM company and Afrezza and take the insulin market. šš» It was great to hear during the presentation today many things which we have discussed on this board for the last several years. Who knows maybe the MNKD Execs read some of this stuff.
As I have said numerous times the CGM business will soon become a commodity market.Ā I thought the breaking news was when Edelman said Google.Ā Steve has been the architect of the Onduo program and Google has also been working with Dexcom for awhile. verily.com/projects/
However when he said Google I thought he was talking about the Google Watch as a CGM and we all know Apple has had their secret IWatch CGM program for awhile.Ā I would not think Dexcom has any rights to the Google Watch.
It was good to hear Dexcom reps should be selling afrezza as we have discussed that too.Ā Kevin Sayer better move fast, real fast to make deal.
IMO, today was by far the best presentation I ever saw from MNKD.Ā Dr. Kendall saying we have a superior "insulin" and it is morally and medically wrong not to have afrezza as the standard of care was a game changer.Ā However the presentation must have been better than I thought as the pps was down.
If Castagna, Kendall, Edelman, and many others see this as game changing, and data supports it, why no partner or buyout? If itās such a game changer, which I wholeheartedly agree, why such a struggle. Honest question. |
|
|
|
Post by gareaudan on Jun 27, 2018 18:24:29 GMT -5
wow! Those are such strong words coming from a very respected man in this field. Thanks mango for posting this, i forgot about this statement. I just dont understand how some peoples can root against this company. Now that the ADA as come and gone and was, imo, a success for mnkd, how long do you think it will take to see a significant rise in the script count ? Apparently, the market dont care about the ADA or the investor meeting but will respond to an increase in revenu. How much longer until the inevitable Kaboom? |
|
|
|
Post by sayhey24 on Jun 27, 2018 18:24:31 GMT -5
golfeveryday - honest answer, read this care.diabetesjournals.org/content/41/Supplement_1/S73Tell me how many times you see inhaled insulin, monomer insulin or afrezza. Prior to this weekend and as Dr. Kendall said today MNKD has never explained what they have. Al assumed everyone knew what he did and hoped SNY would do the right thing. Instead he got ill and SNY screwed all PWDs saving Lantus by screwing afrezza. I got into it with an M/A expert from MRK. They laughed at afrezza after reading the 171 and 175 results. I agreed with them. No way would anyone in that position risk their career without the scientific data especially after what SNY did. |
|
|
|
Post by MnkdWASmyRtrmntPlan on Jun 27, 2018 18:33:49 GMT -5
a CGM company that wants to lead could partner with MNKD/Afrezza or a BP could simply buy a CGM company and Afrezza and take the insulin market. šš» It was great to hear during the presentation today many things which we have discussed on this board for the last several years. Who knows maybe the MNKD Execs read some of this stuff.
As I have said numerous times the CGM business will soon become a commodity market. I thought the breaking news was when Edelman said Google. Steve has been the architect of the Onduo program and Google has also been working with Dexcom for awhile. verily.com/projects/
However when he said Google I thought he was talking about the Google Watch as a CGM and we all know Apple has had their secret IWatch CGM program for awhile. I would not think Dexcom has any rights to the Google Watch.
It was good to hear Dexcom reps should be selling afrezza as we have discussed that too. Kevin Sayer better move fast, real fast to make deal.
IMO, today was by far the best presentation I ever saw from MNKD. Dr. Kendall saying we have a superior "insulin" and it is morally and medically wrong not to have afrezza as the standard of care was a game changer. However the presentation must have been better than I thought as the pps was down.
Sayhey, please explain that last comment about the pps. oh, btw, I totally agree with all you said. Dr. Kendall was great. SOC here we come. Don't forget ... why is pps going down a good thing? |
|
|
|
Post by gareaudan on Jun 27, 2018 18:36:11 GMT -5
It was great to hear during the presentation today many things which we have discussed on this board for the last several years. Who knows maybe the MNKD Execs read some of this stuff.
As I have said numerous times the CGM business will soon become a commodity market.Ā I thought the breaking news was when Edelman said Google.Ā Steve has been the architect of the Onduo program and Google has also been working with Dexcom for awhile. verily.com/projects/
However when he said Google I thought he was talking about the Google Watch as a CGM and we all know Apple has had their secret IWatch CGM program for awhile.Ā I would not think Dexcom has any rights to the Google Watch.
It was good to hear Dexcom reps should be selling afrezza as we have discussed that too.Ā Kevin Sayer better move fast, real fast to make deal.
IMO, today was by far the best presentation I ever saw from MNKD.Ā Dr. Kendall saying we have a superior "insulin" and it is morally and medically wrong not to have afrezza as the standard of care was a game changer.Ā However the presentation must have been better than I thought as the pps was down.
If Castagna, Kendall, Edelman, and many others see this as game changing, and data supports it, why no partner or buyout? If itās such a game changer, which I wholeheartedly agree, why such a struggle. Honest question. i think many are interested but maybe mnkd always ask too much...because they know what they have. Maybe the BP dont want to pay that Much for a product that havent prove to be a good seller but has soon has script raise, it could become an whole different story.imho |
|
|
|
Post by sportsrancho on Jun 27, 2018 18:37:33 GMT -5
We always go down on good news:-)
By the way this is from the SENS ST thread:
@firefox2778 We will have a 360 day implant glucose monitor. You have an insulin inhaler. Which is cool.. when paired with my product. GL
|
|
|
|
Post by sayhey24 on Jun 27, 2018 18:39:48 GMT -5
golfeveryday - you ask "How much longer until the inevitable Kaboom?"
I say Dr. Kendall can make afrezza the standard of care for MDI in 6 months. I say thats worth $1B in sales by 2022.
I say Dr, Kendall can get afrezza into the PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES in 6 months.
I say Dr. Kendall can make afrezza Step 2 for T2s in 18 months. I say thats worth $6B in sales by 2024.
Assume 200 outstanding shares, 50% margin and a P/E of 30. Whats the share price?
When does it go Kaboom? When just a few say that guy Sayhey is right and Dr. Kendall really is going to do what he says.
How fast will that happen? I have NFI but I am taking a nice long vacation during Labor Day and I am fully expecting to enjoy it.
|
|
|
|
Post by boca1girl on Jun 27, 2018 18:40:31 GMT -5
Yes, SENS. Dr. E is a board member. Sports, I mentioned SENS to you last week. I own it. They just did a secondary offering on Monday which drove the price down but they raised $130M. SENS also is being attacked by the shorts. There seems to be a lot of similarities with these small medical companies. Did they already raise that money? The articles I see all say they priced the offering, and that it should close tomorrow (28th). I took that to mean that $130M is what they hope to raise, but is it a done deal? GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of EversenseĀ®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $130.0 million, before deducting estimated offering expenses payable by Senseonics. All of the shares sold in the offering were sold by Senseonics. The offering is expected to close on June 28, 2018, subject to customary closing conditions. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $19.5 million of shares of its common stock. ...Since the news release said sold, it must be a done deal. I had āheardā it was over subscribed. I have concerns wether or not someone would want to get the sensor implanted every 90 days. They already have a 180 day sensor approved for the EU and Roche is their partner and owns 20% of the company. |
|
|
|
Post by sayhey24 on Jun 27, 2018 18:45:47 GMT -5
Tim - "why is pps going down a good thing?" Historically, any time MNKD has had good news the pps goes down. Thats MNKD.
The thing this time is this was not just good news it was game changing news. Peter Richards was not saying those things about afrezza today nor was it Ray U., it was Dr. Kendall. David is the real deal.
Right now afrezza is living rent free in the head of every BP CEO in the diabetes space and you can take that to the bank.
|
|
|
|
Post by goyocafe on Jun 27, 2018 18:46:33 GMT -5
It was great to hear during the presentation today many things which we have discussed on this board for the last several years. Who knows maybe the MNKD Execs read some of this stuff.
As I have said numerous times the CGM business will soon become a commodity market. I thought the breaking news was when Edelman said Google. Steve has been the architect of the Onduo program and Google has also been working with Dexcom for awhile. verily.com/projects/
However when he said Google I thought he was talking about the Google Watch as a CGM and we all know Apple has had their secret IWatch CGM program for awhile. I would not think Dexcom has any rights to the Google Watch.
It was good to hear Dexcom reps should be selling afrezza as we have discussed that too. Kevin Sayer better move fast, real fast to make deal.
IMO, today was by far the best presentation I ever saw from MNKD. Dr. Kendall saying we have a superior "insulin" and it is morally and medically wrong not to have afrezza as the standard of care was a game changer. However the presentation must have been better than I thought as the pps was down.
If Castagna, Kendall, Edelman, and many others see this as game changing, and data supports it, why no partner or buyout? If itās such a game changer, which I wholeheartedly agree, why such a struggle. Honest question. Here are my thoughts on this. 1. CGM companies do not want to align themselves with a single pharmaceutical therapy. They think the broader they keep their market audience, the greater their revenue. 2. The current valuation of MNKD is so off track that no one can make a reasonable offer without looking silly in the eyes of many (shareholders, market analysts, etc) 3. The label has not been improved enough yet to take the claims being made by management to the broader market via advertising or other regulated means, thus making it harder to increase valuation of the company so that #2 can come to fruition. |
|
|
|
Post by sportsrancho on Jun 27, 2018 18:48:39 GMT -5
Where is kite?
How many people were there? Who were they? Were there a lot of discussions after the meeting? How did you feel about how it went? Any pictures:-)
|
|
|
|
Post by mytakeonit on Jun 27, 2018 18:50:34 GMT -5
kite is at the Kodak desk waiting for his old school film to develop.
|
|
|
|
Post by golfeveryday on Jun 27, 2018 18:52:50 GMT -5
golfeveryday - you ask "How much longer until the inevitable Kaboom?" I say Dr. Kendall can make afrezza the standard of care for MDI in 6 months. I say thats worth $1B in sales by 2022. I say Dr, Kendall can get afrezza into the PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES in 6 months. I say Dr. Kendall can make afrezza Step 2 for T2s in 18 months. I say thats worth $6B in sales by 2024. Assume 200 outstanding shares, 50% margin and a P/E of 30. Whats the share price? When does it go Kaboom? When just a few say that guy Sayhey is right and Dr. Kendall really is going to do what he says. How fast will that happen? I have NFI but I am taking a nice long vacation during Labor Day and I am fully expecting to enjoy it. are your 6 months assumptions with mnkd working alone? |
|
|
|
Post by awesomo on Jun 27, 2018 18:57:01 GMT -5
Tim - "why is pps going down a good thing?" Historically, any time MNKD has had good news the pps goes down. Thats MNKD. The thing this time is this was not just good news it was game changing news. Peter Richards was not saying those things about afrezza today nor was it Ray U., it was Dr. Kendall. David is the real deal. Right now afrezza is living rent free in the head of every BP CEO in the diabetes space and you can take that to the bank. Come on now, the world isn't out to get MannKind. The PPS went way up on FDA approval. The PPS went up initially on the announcement of the deal with Sanofi (before people dug into it enough to realize it was not good). The rest of the story? Well after Sanofi and before Mike it was pretty much all bad news. Since Mike took over, he's done a lot of good/great things but all this "good news" hasn't translated into anything tangible yet. Scripts are relatively flat and cash is a major concern still with dilution almost a given in the recent future. So no, the PPS going down is not a good thing especially with the need to sell additional shares at a lower price. It's essentially the market saying "that's nice, prove it". |
|
|
|
Post by sayhey24 on Jun 27, 2018 19:09:07 GMT -5
awesomo - "The PPS went way up on FDA approval", really? It closed at $52.90 on 6/26/2014 and at $50 on 6/27/2014. The last I checked 6/27/14 was approval date.
|
|
